BioSpace News Archive

Personalis, Inc. today announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support clinical diagnostic testing in patients with advanced solid tumors and hematological malignancies.

Laurent Pharmaceuticals Inc. today announced that Luminis Health Research Institute in Annapolis MD, USA, has dosed the first patient in the Phase 3 expansion of the RESOLUTION Phase 2/3 clinical trial evaluating the efficacy of the novel COVID-19 oral antiviral LAU-7b.

National Resilience, Inc. today announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its fourth quarter and full year 2021 financial results before the market opens on Tuesday, March 1, 2022.

Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, reported strong results from a prospective, randomized, double-blind, placebo-controlled clinical trial that studied its migraine headache formulation, UBN RELIEF™.

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022.

Champions Oncology, Inc. announced today a co-development partnership with GigaMune.

Prescient hires three new senior members to support its fast-growing Advisory business.

The American Kidney Fund (AKF) today launched recently enhanced materials in its diversity in clinical trials patient education campaign to equip people of color, who are routinely underrepresented in clinical trials, with accessible information to increase understanding of, and participation in, clinical trials.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced the close of the sale of its leasehold interest in a manufacturing facility in Dunkirk, New York, to ImmunityBio, Inc., for approximately $40 million.